Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study DOI Creative Commons
Insik Song, Minjin Kim, Hangseok Choi

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: July 31, 2023

Abstract Hearing impairment, the third largest health burden worldwide, currently lacks definitive treatments or preventive drugs. This study compared effects of hydrophilic and lipophilic statin on hearing loss using a common database model. retrospective multicenter was conducted in three hospitals South Korea (Anam, Guro, Ansan). We enrolled patients with hyperlipidemia an initial diagnosis. Data were collected during January 1, 2022–December 31, 2021 Observational Health Science Informatics open-source software Common Model database. The primary outcome occurrence first-time following diagnosis, as documented cohort measures interest risk between use. Variables propensity score matching, Cox proportional regression, meta-analysis. Among 37,322 hyperlipidemia, 13,751 (7669 men 6082 women) 23,631 (11,390 12,241 treated statins, respectively. After according to Kaplan–Meier curve, did not significantly differ among hospitals. hazard ratio (HR) male from Anam (0.29, [95% confidence interval (CI), 0.05–1.51]), Guro (HR, 0.56, CI 0.18–1.71]), Ansan (hazard ratio, 0.29, 0.05–1.51]) analyzed regression. Overall effect size 0.40, 0.18–0.91]) estimated meta-analysis, which indicated that users less than statistically significant. Men group had lower impairment those group.

Language: Английский

Statin Use and Reduced Risk of Sudden Sensorineural Hearing Loss in Type 2 Diabetes DOI Open Access

Tongyun Li,

Jr‐Shiang Shiu,

Wan‐Ming Chen

et al.

Otolaryngology, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Abstract Objective To examine the association between statin use and risk of sudden sensorineural hearing loss (SSNHL) in patients with type 2 diabetes (T2D), focusing on type, dosage, treatment duration. Study Design Retrospective cohort study. Setting Taiwan National Health Insurance Research Database. Methods We analyzed T2D diagnosed 2008 2019, stratified into users nonusers lipid‐lowering therapy. Propensity score matching was used to balance baseline characteristics. Multivariable Cox regression, adjusted for competing risks, assessed SSNHL risk, as well all‐cause mortality. Statin exposure based cumulative daily doses. Results The study included 66,120 nonusers. associated a significantly lower (adjusted hazard ratio [aHR], 0.83; 95% CI, 0.74‐0.92; P = .0008) reduced mortality (aHR, 0.55; 0.52‐0.57; < .0001). A dose‐response relationship observed, higher defined doses (cDDDs) linked progressively risk. Hydrophilic statins, particularly rosuvastatin, showed stronger protective effects compared lipophilic statins. Conclusion is mortality, dose‐dependent effects. These findings suggest potential otoprotective benefits statins emphasize importance personalized therapy managing both cardiovascular health this high‐risk population.

Language: Английский

Citations

0
Serum metabolites and risk of sudden sensorineural hearing loss: A Mendelian randomization study DOI

Wenhui Yuan,

Yong Liu, Chao Liu

et al.

Brazilian Journal of Otorhinolaryngology, Journal Year: 2025, Volume and Issue: 91(4), P. 101596 - 101596

Published: April 26, 2025

Language: Английский

Citations

0
The relationship between serum lipid and sudden sensorineural hearing loss DOI

Huang Jia-ying,

XU Yongtian,

Ling Li

et al.

Acta Oto-Laryngologica, Journal Year: 2023, Volume and Issue: 143(2), P. 121 - 126

Published: Feb. 1, 2023

Hyperlipidemia may be part of the important mechanisms for development idiopathic sudden sensorineural hearing loss (ISSNHL).So purpose this study was to evaluate relationship between changes in blood lipid levels and ISSNHL.We enrolled 90 ISSNHL patients our hospital using a retrospective design from 2019.1 2021.12. Blood total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C). Hearing recovery analyzed chi-square test one-way analysis variance (ANONA). Univariate multifactorial Logstic analyses establish LDL-C/HDL-C ratio after adjustment potential confounding factors.In study, 65 (72.2%) had their recovered. All group three (i.e. Excluding no-recovery group) found that LDL/HDL on an upward trend complete slight strongly associated with recovery. multivariate logistic regression high LDL partial group, relative full group. Curve fitting intuitively demonstrates influence lipids prognosis.Our findings suggest LDL. TC, TC/HDL, concentrations closely related pathogenesis ISSNHL.Improving relevant at time admission has good clinical significance improving prognosis ISSNHL.

Language: Английский

Citations

9
Hearing loss during chemotherapy: prevalence, mechanisms, and protection DOI

Lexie Kessler,

Chail Koo,

Claus‐Peter Richter

et al.

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(9), P. 4597 - 4632

Published: Jan. 1, 2024

Ototoxicity is an often-underestimated sequela for cancer patients undergoing chemotherapy, with incidence rate exceeding 50%, affecting approximately 4 million individuals worldwide each year. Despite the nearly 2,000 publications on chemotherapy-related ototoxicity in past decade, understanding of its prevalence, mechanisms, and preventative or therapeutic measures remains ambiguous subject to debate. To date, only one drug, sodium thiosulfate, has gained FDA approval treating chemotherapy. However, utilization restricted. This review aims offer clinicians researchers a comprehensive perspective by thoroughly carefully reviewing available data current evidence. Chemotherapy-induced characterized four primary symptoms: hearing loss, tinnitus, vertigo, dizziness, originating from both auditory vestibular systems. Hearing loss predominant symptom. Amongst over 700 chemotherapeutic agents documented various databases, seven are reported induce loss. While molecular mechanisms caused two platinum-based drugs extensively explored, pathways behind action other five primarily speculative, rooted their properties side effects. Cisplatin attracts majority attention among these drugs, encompassing around two-thirds literature regarding chiefly manifests through outer hair cells, possibly resulting damages directly cisplatin uptake secondary effects stria vascularis. Both direct indirect influences contribute ototoxicity, while it still debated which path dominant where target located. Candidates protection against also discussed, novel strategies methods showing promise horizon.

Language: Английский

Citations

3
Statins protect mice from high-decibel noise-induced hearing loss DOI Open Access

Frédéric F. Depreux,

Lyubov Czech,

Hunter Young

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 163, P. 114674 - 114674

Published: April 21, 2023

No medical interventions for noise induced hearing loss (NIHL) are approved by the Food and Drug Administration (USA). Here, we evaluate statins in CBA/CaJ mice as potential drugs loss. Direct delivery of fluvastatin to cochlea oral lovastatin were evaluated. Baseline was assessed using Auditory Brain Stem Responses (ABRs). For fluvastatin, a cochleostomy surgically created basal turn novel, laser-based procedure, through which catheter attached mini-osmotic pump inserted. The filled with solution 50 µM fluvastatin+carrier or carrier alone continuous cochlea. Mice exposed one octave band (8-16 kHz x 2 h 110 dB SPL). In our past work guinea pigs, protected contralateral this study mice, also 1-4 weeks after exposure. At two post exposure, ABR thresholds at 4, 8, 12, 16, 32 elevated, expected, noise+carrier treated approximately 9-, 17-, 41-, 29-, 34-dB, respectively. Threshold elevations smaller noise+fluvastatin about 2-, 6-, 20-,12- 12-dB Survival inner hair cell synapses not over these frequencies. Lovastatin delivered gavage showed lower threshold shifts than alone. These data show that direct statin protects against NIHL.

Language: Английский

Citations

8
Pitavastatin protects against neomycin-induced ototoxicity through inhibition of endoplasmic reticulum stress DOI Creative Commons
Yunhao Wu, Wei Meng, Ming Guan

et al.

Frontiers in Molecular Neuroscience, Journal Year: 2022, Volume and Issue: 15

Published: Aug. 3, 2022

Irreversible injury to inner ear hair cells induced by aminoglycoside antibiotics contributes the formation of sensorineural hearing loss. Pitavastatin (PTV), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been reported exert neuroprotective effects. However, its role in aminoglycoside-induced loss remains unknown. The objectives this study were investigate beneficial effects, as well mechanism action PTV against neomycin-induced ototoxicity. We found that remarkably reduced cell mouse cochlear explants and promoted auditory HEI-OC1 survival after neomycin stimulation. also observed brainstem response threshold was increased significantly pretreatment with mice. Furthermore, endoplasmic reticulum stress attenuated treatment through inhibition PERK/eIF2α/ATF4 signaling. Additionally, we suppressed RhoA/ROCK/JNK signal pathway, which activated stimulation cells. Collectively, our results showed might serve promising therapeutic agent

Language: Английский

Citations

8
Enhancing the human health and lifespan: a targeted strategy emphasizing statins DOI
Edward J. Calabrese, Peter Pressman

Biogerontology, Journal Year: 2024, Volume and Issue: 25(5), P. 883 - 890

Published: May 29, 2024

Language: Английский

Citations

1
No causal relationship serum lipids on age-related hearing loss based on Mendelian randomized evidence DOI

Tianyi Ni,

Z. Shen,

Xiuling Lu

et al.

Hearing Research, Journal Year: 2024, Volume and Issue: 453, P. 109128 - 109128

Published: Oct. 2, 2024

Language: Английский

Citations

1
Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study DOI Creative Commons
Insik Song, Minjin Kim, Hangseok Choi

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: July 31, 2023

Abstract Hearing impairment, the third largest health burden worldwide, currently lacks definitive treatments or preventive drugs. This study compared effects of hydrophilic and lipophilic statin on hearing loss using a common database model. retrospective multicenter was conducted in three hospitals South Korea (Anam, Guro, Ansan). We enrolled patients with hyperlipidemia an initial diagnosis. Data were collected during January 1, 2022–December 31, 2021 Observational Health Science Informatics open-source software Common Model database. The primary outcome occurrence first-time following diagnosis, as documented cohort measures interest risk between use. Variables propensity score matching, Cox proportional regression, meta-analysis. Among 37,322 hyperlipidemia, 13,751 (7669 men 6082 women) 23,631 (11,390 12,241 treated statins, respectively. After according to Kaplan–Meier curve, did not significantly differ among hospitals. hazard ratio (HR) male from Anam (0.29, [95% confidence interval (CI), 0.05–1.51]), Guro (HR, 0.56, CI 0.18–1.71]), Ansan (hazard ratio, 0.29, 0.05–1.51]) analyzed regression. Overall effect size 0.40, 0.18–0.91]) estimated meta-analysis, which indicated that users less than statistically significant. Men group had lower impairment those group.

Language: Английский

Citations

3